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Natural experiment examining impact of aggressive
screening and treatment on prostate cancer mortality in
two fixed cohorts from Seattle area and Connecticut
Grace Lu-Yao, Peter C Albertsen, Janet L Stanford, Therese A Stukel, Elizabeth S Walker-Corkery,
Michael J Barry
Abstract
Objective To determine whether the more intensive
screening and treatment for prostate cancer in the
Seattle-Puget Sound area in 1987-90 led to lower
mortality from prostate cancer than in Connecticut.
Design Natural experiment comparing two fixed
cohorts from 1987 to 1997.
Setting Seattle-Puget Sound and Connecticut
surveillance, epidemiology, and end results areas.
Participants Population based cohorts of male
Medicare beneficiaries aged 65-79 drawn from the
Seattle (n=94 900) and Connecticut (n=120 621)
areas.
Main outcome measures Rates of screening for
prostate cancer, treatment with radical prostatectomy
and external beam radiotherapy, and prostate cancer
specific mortality.
Results The prostate specific antigen testing rate in
Seattle was 5.39 (95% confidence interval 4.76 to 6.11)
times that of Connecticut, and the prostate biopsy rate
was 2.20 (1.81 to 2.68) times that of Connecticut
during 1987-90. The 10 year cumulative incidences of
radical prostatectomy and external beam
radiotherapy up to 1996 were 2.7% and 3.9% for
Seattle cohort members compared with 0.5% and
3.1% for Connecticut cohort members. The adjusted
rate ratio of prostate cancer mortality up to 1997 was
1.03 (0.95 to 1.11) in Seattle compared with
Connecticut.
Conclusion More intensive screening for prostate
cancer and treatment with radical prostatectomy and
external beam radiotherapy among Medicare
beneficiaries in the Seattle area than in the
Connecticut area was not associated with lower
prostate cancer specific mortality over 11 years of
follow up.
Introduction
During the early 1990s the incidence of prostate
cancer in the United States rose dramatically after the
introduction of testing for prostate specific antigen.
The subsequent decline in incidence probably repre-
sents depletion of prevalent cases from the pool of
men undergoing screening.1 2 In the mid-1990s popu-
lation based prostate cancer mortality peaked and then
decreased by about 15%.2 3 Although the decline in
mortality may be attributable to screening, several
studies have highlighted difficulties in making infer-
ences about causation from cross sectional population
based data.4–6
The dissemination of prostate cancer screening
and treatment was associated with substantial regional
variations.7 Several studies have documented that the
frequency of prostate specific antigen testing, prostate
biopsy, and radical prostatectomy among Medicare age
men in the Seattle-Puget Sound area was initially
higher than in Connecticut.1 7
If the recent national downturn in mortality from
prostate cancer is in part attributable to screening and
treatment, then an earlier and larger decline in prostate
cancer mortality would be expected in Seattle than in
Connecticut. The age adjusted prostate cancer death
rates in the two regions were almost identical before
prostate specific antigen testing (155.8 v 155.6 deaths
per 100 000 person years for white men aged 65-79
and 317.2 v 323.3 deaths per 100 000 person years for
African-American men aged 65-79 from 1977 to
1986) (US data by SEER region, age, and race provided
L Ries, Cancer Statistics Branch, National Cancer
Institute).
This paper presents an 11 year longitudinal study
of two cohorts of male Medicare beneficiaries from the
Seattle-Puget Sound area and Connecticut exposed to
different intensities of prostate cancer screening and
treatment during the “early prostate specific antigen
era,” which we defined a priori as 1987-90. The institu-
tional review boards of Partners Healthcare System
and the participating institutions approved the study.
Methods
Data sources and inclusion criteria
Medicare provides health insurance for people aged
65 and over in the United States and is administered by
the Centers for Medicare and Medicaid Services,
formerly the Health Care Financing Administration.
Medicare pays treatment claims under two pro-
grammes: part A covers hospital, nursing home, and
home health care, and part B covers physician and
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surveillance, epidemiology, and end results (SEER)
program collects cancer incidence and survival data
from 11 population based cancer registries covering
approximately 14% of the US population.
We used four specific data sources for this study:
Medicare denominator and vital status files, SEER-
Medicare linked database, and local SEER registry
data. We used the denominator and vital status files,
containing information on county of residence, to
identify men in the participating SEER areas. Medicare
analysts then matched the preliminary study cohort
with an existing SEER-Medicare linked file and sent
the data to the two local SEER registries. The SEER
registries excluded men diagnosed as having prostate
cancer before 1987 and supplied updated information
on survival and cause of death on the remainder.
To create the SEER-Medicare linked database, each
SEER registry sends Medicare information on each
person diagnosed as having cancer in its area.
Medicare then uses a deterministic matching algo-
rithm to link this data with claims files. To ensure confi-
dentiality, unique identifiers are assigned. We obtained
data from the most recent linkage for 1987-96, for
which a 93% match rate was achieved.8 The file
included prostate specific antigen, prostate biopsy, and
radical prostatectomy claims for 100% of prostate
cancer cases up to 1996 and prostate specific antigen
and biopsy claims for a 5% sample of cases without
prostate cancer only up to 1993.
We included men who were Medicare beneficiaries
aged 65-79 without prostate cancer as of 1 January
1987 and resident within the Seattle-Puget Sound or
Connecticut SEER region from 1 January 1987 to 31
December 1990.
Measurement of screening and treatment intensity
We used rates of claims for both prostate specific anti-
gen tests and prostate biopsies as measures of
screening intensity. Biopsy rates reflect the intensity of
screening with digital rectal examinations as well as
prostate specific antigen. As prostate specific antigen
and biopsy data were available for 100% of cancer
cases and 5% of non-cancer cases up to 1993, we calcu-
lated the biopsy rate by using a weight of 1 for
non-cancer cases and 0.05 for cancer cases. We identi-
fied prostate specific antigen tests by current proce-
dural terminology codes 86316 and 84153 (first
available in 1988) and biopsies or ultrasound guided
biopsies by codes 55700, 55705, 76942, and 76943. We
excluded a small percentage of beneficiaries enrolled
in health maintenance organisations or without part B
coverage from the analyses of screening, as their claims
were incomplete. We excluded prostate specific antigen
tests and biopsies that occurred after diagnosis of pros-
tate cancer.
In the prostate specific antigen era screening drives
incidence of prostate cancer1; we therefore used
prostate cancer incidence as a secondary measure of
screening intensity. Prostate cancer incidence data
were available up to 1996.
Data on the use of radical prostatectomy were
available for all cancer cases from 1987 to 1996. We
used SEER data alone to document the use of external
beam radiation within four months of diagnosis for the
same years.
Prostate cancer mortality
The primary end point for this study was prostate
cancer mortality for the two cohorts from 1987 to
1997. We based this on survival data provided directly
from the SEER registries.
Statistical methods
We expressed estimated rates of death, screening, and
treatment as numbers of events per 100 000 person
years. We summed the number of patients alive to the
end of the year and half of the patients who died or
were lost to follow up during the year to calculate the
person years in each cohort annually. We used Poisson
regression models to calculate adjusted relative rates of
screening, treatment, and death between regions.9 This
method produces similar relative rate estimates to Cox
regression,10 as the grouped one year time intervals are
short.11 We obtained SEER-Medicare linked data on all
outcomes grouped by age (65-69, 70-74, 75-79 years),
year of study, and registry area. All analyses used the
age group-year-area stratum as the unit of analysis,
weighted by the number in the stratum. All models
controlled for age group, race, area of residence, study
year, and an age-race interaction. We censored follow
up at year of death or 1997, whichever was earlier. We
incorporated variance overdispersion in the estimates
of all standard errors to account for possible clustering
of outcomes within strata due to common life or prac-
tice style influences.9 This adjustment increased the
width of the confidence intervals negligibly for prostate
specific antigen and biopsy, 1.5-fold for radical prosta-
tectomy, and 2.1-fold for cancer incidence. Mortality
was not clustered within strata, so we report the
Poisson based rate ratios and confidence intervals.
We used life table methods to determine the cumu-
lative incidence of a first prostate specific antigen test
(1988-93) and of a prostate cancer diagnosis, radical
prostatectomy, and external beam radiation (1987-96)
in the two regions.10 To show population based prostate
cancer mortality trends over time in the two study
regions we present cross sectional death rates, adjusted
to the age of the study population in 1992. All statisti-
cal tests were performed at the 5% level and were two
sided.
Results
Table 1 shows the race and age distributions for the
215 521 eligible men in both cohorts. Cohort
members in the Seattle-Puget Sound region were 5.39
(95% confidence interval 4.76 to 6.11) times more
likely to undergo prostate specific antigen testing in
1988-90 (table 2) and 2.20 (1.81 to 2.68) times more
likely to undergo prostate biopsy in 1987-90 (table 3)
Table 1 Race and age distributions for the members of the Seattle-Puget Sound and
Connecticut study cohorts. Values are numbers (percentages)
Characteristic Seattle-Puget Sound (n=94 900) Connecticut (n=120 621)
Race:
White 88 863 (93.6) 114 785 (95.2)
African-American 1 963 (2.1) 3 882 (3.2)
Other 4 074 (4.3) 1 954 (1.6)
Age (years) in 1987:
65-69 43 249 (45.6) 53 310 (44.2)
70-74 31 544 (33.2) 41 167 (34.1)
75-79 20 107 (21.2) 26 144 (21.7)
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than their counterparts in Connecticut. Differences in
prostate specific antigen testing and biopsy rates
narrowed considerably in 1991-3; the Seattle to
Connecticut adjusted rate ratio was 1.61 (1.48 to 1.75)
for prostate specific antigen and 1.14 (0.93 to 1.40) for
biopsy. Figure 1 displays the cumulative incidence of a
first prostate specific antigen test among cohort mem-
bers in the two regions from 1988 to 1993.
Prostate cancer incidence reflects screening rates
(fig 2). The adjusted cumulative incidence of prostate
cancer was 93% (81% to 107%) higher among men in
Seattle-Puget Sound than in Connecticut in 1987-90.
The difference in incidence diminished over time;
during 1991-6 the cumulative prostate cancer inci-
dence was only 11% (4% to 18%) higher in the Seattle
area.
Between 1987 and 1990 men in the Seattle area
were more likely to have radical prostatectomy or
external beam radiation than their counterparts in
Connecticut. Men in the Seattle area had a 5.9-fold (5.0
to 6.9) higher rate of radical prostatectomy and
2.3-fold (2.2 to 2.5) higher rate of external beam radia-
tion during 1987-90. The 10 year cumulative
incidences of radical prostatectomy and external beam
radiation from 1987 to 1996 were 2.7% and 3.9% for
Seattle-Puget Sound cohort members and 0.5% and
3.1% for Connecticut cohort members (fig 3).
No significant difference in prostate cancer
mortality existed between the Seattle and Connecticut
cohorts over the entire 11 year follow up period. The
adjusted rate ratio of prostate cancer mortality to 1997
was 1.03 (0.95 to 1.11) in Seattle compared with Con-
necticut (table 4). As any effect of more aggressive
screening and treatment on mortality may have been
delayed, we compared prostate cancer mortality
separately for the earlier (1987-92) and later (1993-7)
years of follow up. No significant differences occurred
in either period—rate ratios 0.97 (0.81 to 1.16) versus
1.08 (0.98 to 1.20). Fig 4 displays cross sectional
prostate cancer mortality for men aged 65-79 from
1987 to 1997, documenting similar decreases in both
areas.
Discussion
Given the greater intensity of screening, diagnosis, and
treatment documented among cohort members in the
Seattle-Puget Sound area than in Connecticut, we
would have expected to see lower prostate cancer mor-
tality in the Seattle region over time. However, we
found no significant difference in prostate cancer mor-
tality over 11 years of follow up. The confidence inter-
val around the rate ratio for mortality was inconsistent
with more than a 5% reduction in prostate cancer
Table 2 Prostate specific antigen (PSA) testing rates for study cohort members with
Medicare part A and B coverage, 1988-90, rate ratio adjusted for age and race
Age (years)

















65-69 505/4415 11 448 130/6357 2043
70-74 356/3132 11 381 113/5186 2176
75-79 261/1959 13 322 78/3058 2557
Total 1122/9506 11 803 321/14 601 2199 5.39 (4.76 to 6.11)
Table 3 Prostate biopsy rates for study cohort members with Medicare part A and B

















65-69 110/6019 1822 71/8651 818
70-74 92/4327 2124 60/7136 842
75-79 40/2747 1471 38/4275 882


























First prostate specific antigen test
Fig 1 Unadjusted cumulative incidence of a first prostate specific
antigen test for study cohort members in the Seattle-Puget Sound



























Fig 2 Unadjusted 10 year cumulative incidence of prostate cancer
for study cohort members in the Seattle-Puget Sound and
Connecticut areas, 1987-96
Table 4 Prostate cancer specific mortality by age, and age adjusted mortality rate ratios, 1987-97
Age (years)
Seattle-Puget Sound Connecticut Age adjusted mortality rate
ratio, Seattle/Connecticut
(95% CI)No of deaths/ person years
Mortality per 100 000
person years
No of deaths/ person
years
Mortality per 100 000
person years
65-69 379/396 489 95.6 442/481 372 91.8
70-74 394/261 599 150.6 515/336 783 152.9
75-79 307/144 726 212.1 386/181 462 209.6
Total 1080/802 813 134.5 1343/1 002 316 134.0 1.03 (0.95 to 1.11)
Papers
page 3 of 6BMJ VOLUME 325 5 OCTOBER 2002 bmj.com
mortality in Seattle. Moreover, the overall drop in
prostate cancer mortality seemed similar in the two
regions (fig 4). The results of this study therefore do not
support the hypothesis that the intensity of screening
and treatment with surgery or radiation was related to
the reduction in prostate cancer mortality seen in the
two regions.
A recent report has documented decreases in
population based prostate cancer mortality in Tyrol
compared with other states in Austria after the
introduction of mass prostate specific antigen screen-
ing in Tyrol.12 Our results are in conflict with these for
unclear reasons; although the intensity of screening in
Tyrol seems similar to that in the Seattle area (about
two thirds of men screened at least once over five
years), the intensity of treatment in Tyrol and the inten-
sities of both screening and treatment in the rest of
Austria were not presented in that report.
Limitations of the study
Our study has several limitations. Firstly, the cohorts
included only men aged 65 and over in 1987. Screen-
ing and treatment for prostate cancer may have a
larger impact on younger men. However, as prostate
cancer death is rare before age 70,3 if recent decreases
in prostate cancer mortality in the United States are
attributable to screening and treatment with surgery
and radiation this impact would almost certainly be
seen among Medicare age men.
Secondly, during 1987-90 Medicare did not
routinely pay for prostate specific antigen screening
tests. Claims may not have always been submitted,
therefore, and numbers of prostate specific antigen
tests may be underestimated. Nevertheless, the relative
rates of testing between the two regions should not be
biased, and the differences in biopsies and incidence
confirm the higher intensity of screening in the Seattle
area.
Thirdly, follow up over 11 years may not have been
long enough to see a difference in prostate cancer
mortality. However, if the decreases in population
based prostate cancer mortality noted in both these
areas (fig 4) are indeed attributable to screening and
treatment with surgery or radiation, the time frame
should have been sufficient to see an effect.
Nevertheless, further follow up is planned.
Fourthly, we used SEER data to capture new
diagnoses of prostate cancer, so records of diagnosis or
cause of death for cohort members who moved out of
their SEER areas after 1990 were unavailable. A differ-
ential rate of death from prostate cancer among men
who moved after 1990 could introduce bias. However,
Medicare enrolment files indicated that less than 1% of
cohort members without prostate cancer moved out of
their regions before dying. As only about 3% of these
men would be expected to die of prostate cancer, the
impact of any differential rate of death from prostate
cancer should be minimal.
Fifthly, as the primary outcome measure was pros-
tate cancer specific mortality a differential assignment
of cause of death among prostate cancer patients in the
two regions could bias comparisons. Earlier studies
have shown a relatively high agreement (over 90%)
between medical records and underlying causes of
death as recorded on death certificates.13 Our group
has shown a high level of agreement between medical
records and the cause of death as listed on the death
certificate among patients with prostate cancer in
Connecticut—91% for men dying in 1995 and 82% for
men dying in 1985—with no change in the coding of
cause of death among prostate cancer patients dying in
the pre-prostate specific antigen (1985) and prostate
specific antigen (1995) eras.14 Moreover, as part of the
current study, we replicated this analysis for patients
with prostate cancer who died in the Seattle area in
1995; once again, the agreement between death certifi-
cates and medical records on cause of death was
greater than 90%.15
Sixthly, prostate specific antigen and biopsy data
were incomplete for men enrolled in a Medicare health










































Fig 3 Unadjusted 10 year cumulative incidence of radical
prostatectomy (top) and external beam radiotherapy (bottom) for



























Fig 4 Age adjusted prostate cancer mortality per 100 000 person
years for men in Seattle-Puget Sound and Connecticut on the basis
of cross sectional data, 1987-97 (adjusted to the age composition of
the entire study cohort: 48.3% aged 70-74, 33.3% aged 75-79,
18.4% aged 80-84 as of 1 January 1992). (US data by SEER region,
age, and race provided by L Ries, Cancer Statistics Branch, National
Cancer Institute)
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ing the early prostate specific antigen era. The men
enrolled in health maintenance organisations were
included in the primary analyses of treatment and
mortality rates. Perhaps men enrolled in health
maintenance organisations were not as intensively
screened in the Seattle area, which would tend to dilute
any mortality benefit attributable to screening.
However, excluding men enrolled in health mainte-
nance organisations from the mortality analysis did
not affect the results: rate ratio=1.0 (0.9 to 1.1).
Finally, men in the two cohorts may have differed
on important risk factors for prostate cancer. Although
only randomised trials can yield truly unbiased
estimates of the efficacy of screening and treatment on
prostate cancer mortality, their external validity might
be limited.16 This longitudinal cohort study, which
applied uniform selection criteria at “zero time” for
determining eligibility and included a broad represen-
tation of the population at risk, may provide
complementary and important insights into what
might be expected at the population level.
Why has mortality decreased?
This study does not shed light on the reasons for the
decline in prostate cancer mortality in these two
regions. More effective treatment for advanced disease
may have improved mortality in both areas; rates of
androgen deprivation, a primary treatment for
advanced prostate cancer, could not be tracked with
the data available. Additionally, changes in lifestyle or
environmental factors that may affect the progression
of prostate cancer may have had a role in these
mortality trends.
Conclusion
More intensive screening for prostate cancer and treat-
ment with surgery or radiation among a cohort of
Medicare beneficiaries in the Seattle-Puget Sound area
compared with a cohort in Connecticut has not led to
significantly lower mortality from prostate cancer over
11 years. Longer follow up will be necessary to fully
assess the outcome of this natural experiment.
Meanwhile, ongoing randomised trials assessing the
effectiveness of screening and treatment for prostate
cancer should be supported.
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What is already known on this topic
Screening for prostate cancer with the prostate
specific antigen test is widely practised in the
United States and has resulted in a remarkable
increase in incidence of diagnosed disease
Randomised trials are under way to determine
whether early detection and aggressive treatment
reduce mortality from prostate cancer
Recent reductions in prostate cancer mortality in
the United States have been attributed to
screening and treatment, raising questions about
whether continuing the trials is ethical
What this study adds
Prostate cancer screening and treatment were
much more intensive among men in the
Seattle-Puget Sound area than in Connecticut
early in the “prostate specific antigen era”
Over 11 years of follow up, no difference in
prostate cancer mortality was seen in the two
cohorts
The lack of association between more intensive
screening and treatment and lower prostate cancer
mortality suggests that trials should continue in
order to settle this question
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16 Concato J, Shah N, Horwitz RI. Randomized, controlled trials,
observational studies, and the hierarchy of research designs. N Engl J Med
2000;342:1887-92.
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